Target intelligence / Profile preview

Klebsiella pneumoniae lipopolysaccharide (K. pneumoniae LPS)

Target
K. pneumoniae LPS
Molecular classification
Lipopolysaccharide, Bacterial surface antigen, Endotoxin, Glycan
01

Overview

Klebsiella pneumoniae lipopolysaccharide (LPS) is a major structural component of the outer membrane of the Gram-negative bacterium Klebsiella pneumoniae, a leading cause of healthcare-associated infections, neonatal sepsis, and multidrug-resistant pneumonia. Structurally, K. pneumoniae LPS consists of three domains: the endotoxic lipid A, a conserved core oligosaccharide, and the highly immunogenic O-antigen (O-polysaccharide). LPS plays a critical role in bacterial virulence and immune evasion by protecting the pathogen from complement-mediated killing and inhibiting host antimicrobial peptides. Because of its abundance and relatively limited serological diversity compared to the capsular polysaccharide, K. pneumoniae LPS is a highly attractive target for novel immunotherapies and vaccines. Therapeutic strategies targeting this molecule include polymyxin antibiotics (such as polymyxin B and colistin), which bind to lipid A to disrupt the bacterial membrane, and bioconjugate vaccines like Kleb4V, which elicit protective antibodies against predominant O-antigen serotypes. Additionally, monoclonal antibodies are being developed to promote opsonophagocytic killing and neutralize endotoxin-mediated inflammatory responses.

Other names
Klebsiella pneumoniae LPSKlebsiella pneumoniae O-antigenKlebsiella pneumoniae lipopolysaccharide O-antigenKlebsiella pneumoniae endotoxinK. pneumoniae lipopolysaccharide
02

Mechanism of action

Polymyxins bind to the lipid A portion of the lipopolysaccharide, disrupting the outer membrane and causing cell death. Vaccines and monoclonal antibodies target the O-antigen or core-lipid A regions to induce protective humoral immunity, promote opsonophagocytic killing, and neutralize endotoxin activity.

03

Biological functions

Immune evasionBacterial virulenceComplement resistanceEndotoxemia inductionInflammatory response activation
04

Disease associations

InfectionSepsisInflammation
05

Safety considerations

Endotoxicity and risk of systemic inflammatory response syndromeNephrotoxicity and neurotoxicity associated with polymyxin treatmentAntigenic diversity and capsule masking limiting antibody accessibilityLipid A modifications leading to polymyxin resistance
06

Interacting drugs

2 more in the full profile.

07

Biomarkers

Anti-LPS IgG titersAnti-LPS IgA titersOpsonophagocytic killing activitySerum bactericidal activityKlebsiella pneumoniae O-serotype

Beyond the preview

Go deeper on Klebsiella pneumoniae lipopolysaccharide (K. pneumoniae LPS).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Klebsiella pneumoniae lipopolysaccharide (K. pneumoniae LPS).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call